<DOC>
	<DOCNO>NCT00897481</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help study cancer future . PURPOSE : This laboratory study look tumor tissue sample patient melanoma undergone sentinel lymph node biopsy .</brief_summary>
	<brief_title>Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy</brief_title>
	<detailed_description>OBJECTIVES : - Develop predictive model sentinel lymph node biopsy positivity patient melanoma undergone sentinel lymph node biopsy . - Develop survival model relapse base sentinel lymph node biopsy positivity . - Assess genetic determinant primary melanoma predict metastatic phenotype thereby improve understand biology metastasis melanoma . OUTLINE : This retrospective , case-controlled , multicenter study . Patients stratify accord Breslow thickness tumor ( 0.75-1.50 mm v 1.51- 4 mm v &gt; 4 mm ) gender . Archived tumor tissue analyze immunohistochemistry ( IHC ) AP2 , vascular endothelial growth factor , MMP 2 , MCM4 , others , feasible . Sentinel node biopsy analyze IHC CD31 , LYVE-1 , D2-40 expression . RNA DNA also extract genetic expression study mutation analysis ( e.g. , BRAF , NRAS , PTEN , CDKN2A ) . Patient data related relapse recurrence collect , available . Peer review funded endorsed Cancer Research UK PROJECTED ACCRUAL : A total 1,000 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis cutaneous melanoma Breslow thickness &gt; 0.75 mm Has undergone sentinel lymph node biopsy No primary melanoma originate skin No multiple primary melanoma Currently clinical followup OR discharge follow within past 3 month PATIENT CHARACTERISTICS : No malignancy except nonmelanoma skin cancer cervical carcinoma situ PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IA melanoma</keyword>
	<keyword>stage IB melanoma</keyword>
	<keyword>stage IIA melanoma</keyword>
	<keyword>stage IIB melanoma</keyword>
	<keyword>stage IIC melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>